与铜代谢相关的生物标志物和糖尿病病的治疗标
Qiaofang Yan1,2,3, Yuanyuan Du4, Fei Huang1,2
1The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
PeerJ
|December 24, 2025
概括
这项研究确定了五个铜代谢基因作为早期糖尿病病 (DN) 诊断和潜在治疗点的新生物标志物. 这些生物标志物对改善诊断准确性和指导DN的治疗策略有前途.
科学领域:
- 生物化学 生化学
- 遗传学 是一个遗传学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 糖尿病病 (DN) 是糖尿病的严重并发症,诊断标志物和治疗方法有限.
- 异常的铜代谢在糖尿病及其并发症中越来越多地被认可.
- 目前的研究缺乏有效的DN生物标志物和治疗方法.
研究的目的:
- 确定与铜代谢相关的新生物标志物,用于早期诊断DN.
- 探索潜在的治疗药物,针对这些生物标志物进行DN治疗.
- 阐明铜代谢在DN病变发生中的作用.
主要方法:
- 利用基因表达总体 (GEO) 和基因卡片数据集用于与铜代谢相关的基因 (CMG).
- 使用生物信息学分析确定差异表达的CMG (DE-CMG) 和枢纽基因.
- 在高葡萄糖处理的HK-2细胞中通过qRT-PCR验证了生物标志物,并构建了一个预测模型.
主要成果:
- 五个枢纽基因 (CD36,CCL2,CASP3,LPL,APOC3) 被确定为DN的潜在诊断生物标志物.
- 这些生物标志物在集体使用时显示出更高的诊断准确性和特异性.
- 枢纽基因表达与估计的膜过率 (eGFR) 和免疫细胞透相关.
结论:
- 确定了与铜代谢相关的关键基因,作为DNA的潜在诊断和治疗标.
- 这些生物标志物为早期DN检测和管理提供了新的途径.
- 这些发现有助于理解铜代谢在DNA病理学中的作用.
相关概念视频
01:29Therapeutic Drug Monitoring: Affecting Factors
170
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
170
01:15Diabetes: Management and Pharmacotherapy
844
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
844
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
165
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
165
01:24Chronic Kidney Disease II: Clinical Manifestations
520
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
520
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
197
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
197